SequelSEC

Alkermes plc. ALKS

Pharmaceutical Preparations · CIK 0001520262 · Fiscal year ends 1231

Revenue
$1.67B
Fiscal year ended 2026-06-30
Operating income
$117.26M
Fiscal year ended 2026-06-30
Free cash flow
$221.65M
Fiscal year ended 2026-06-30

Alkermes plc. (ALKS) reported revenue of $1.67B and net income of $66.12M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Alkermes plc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Alkermes plc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.67B
Cost of revenue$257.49M
Gross profit$1.41B
Operating income$117.26M
Net income$66.12M
Research & development$391.04M
Weighted-average diluted sharesUnavailable
Pretax income$97.32M
Income tax expense$31.20M
Diluted EPSUnavailable
Selling, general & administrative$841.19M
General & administrative$295.36M
Selling & marketing$545.83M

Balance

Alkermes plc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$511.53M
Total assets$4.39B
Current assets$1.52B
Total liabilities$2.58B
Current liabilities$662.09M
Total equity incl. NCI$1.81B
Temporary (mezzanine) equityUnavailable
Inventory$298.96M
Accounts receivable$456.48M
Goodwill$594.27M
Long-term debt$1.48B
Accounts payable$142.86M

Cash flow

Alkermes plc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$251.18M
Capital expenditures$29.53M
Investing cash flow-$1.76B
Financing cash flow$1.50B
Net change in cash-$9.67M
Stock-based compensation$118.41M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$61.63M

Derived

Alkermes plc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$221.65M
Gross margin84.6%
Operating margin7.0%
FCF margin13.3%
SBC / revenue7.1%
Current ratio2.30x
Revenue YoY growth10.8%
Net margin4.0%
R&D / revenue23.4%
CapEx / revenue1.8%
Long-term debt / equity0.82x
Effective tax rate32.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALKS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-28View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.